DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Afuresertib is an investigational drug.
There have been 10 clinical trials for Afuresertib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2015.
The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Prostatic Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, Laekna Limited, and Novartis Pharmaceuticals.
There are fifty-seven US patents protecting this investigational drug and four hundred and eighty-one international patents.
Recent Clinical Trials for Afuresertib
|Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer||Laekna LLC||Phase 1|
|Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian||Laekna Limited||Phase 2|
|Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC||Laekna Limited||Phase 1/Phase 2|
Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Afuresertib||Get Started Free||Treatment of ophthalmic conditions by selectively removing senescent cells from the eye||Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN)||Get Started Free|
|Afuresertib||Get Started Free||.beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof||Quadriga Biosciences, Inc. (Los Altos, CA)||Get Started Free|
|Afuresertib||Get Started Free||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||Get Started Free|
|Afuresertib||Get Started Free||Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population||UNITY BIOTECHNOLOGY, INC. (Brisbane, CA) BUCK INSTITUE FOR RESEARCH ON AGING (Novato, CA) MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (Rochester, MN)||Get Started Free|
|Afuresertib||Get Started Free||Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways||Asana BioSciences, LLC (Lawrenceville, NJ)||Get Started Free|
|Afuresertib||Get Started Free||Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof||ZHEJIANG UNIVERSITY (Zhejiang, CN) SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (Shanghai, CN)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Afuresertib||Australia||AU2015211021||2034-01-28||Get Started Free|
|Afuresertib||Australia||AU2020244600||2034-01-28||Get Started Free|
|Afuresertib||Brazil||BR112016017564||2034-01-28||Get Started Free|
|Afuresertib||Canada||CA2939121||2034-01-28||Get Started Free|
|Afuresertib||Canada||CA3100140||2034-01-28||Get Started Free|
|Afuresertib||China||CN106163557||2034-01-28||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|